Arteries Embolization Therapeutic/*adverse effects/methods/standards Humans Kallikreins/blood Lower Urinary Tract Symptoms/blood/etiology/*therapy Male Practice Guidelines as Topic Prostate/blood supply Prostate-Specific Antigen/blood Prostatic Hyperplasia/blood/complications/*therapy Quality of Life Treatment Outcome *arteries *embolization *investigational *prostatic hyperplasia *therapeutic *therapies *treatment outcome

*Ejaculation Humans Male Prostatic Hyperplasia/complications Prostatism/etiology Randomized Controlled Trials as Topic Sexual Dysfunction Physiological/*etiology/physiopathology Urologic Surgical Procedures Male/*adverse effects benign prostatic hyperplasia decreased ejaculation ejaculatory dysfunction lower urinary tract symptoms painful ejaculation retrograde ejaculation

Humans Aged Cystectomy/methods *Urinary Bladder Neoplasms/surgery Urinary Bladder *Urinary Diversion/methods Hospital Mortality Bladder cancer Complications Epidemiology Mortality Radical cystectomy Urinary diversions

Humans *Transurethral Resection of Bladder Neoplasm Recurrence Local/pathology *Urinary Bladder Neoplasms/diagnosis/surgery/pathology Prognosis Urologic Surgical Procedures Cystectomy Bladder cancer Css Os Pfs Rfs Transurethral resection of bladder tumors financial ties to disclose.

膀胱癌 吉西他滨 表柔比星 膀胱灌注 系统评价

膀胱肿瘤 超声造影 TNM分期 系统评价

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

膀胱肿瘤 内窥镜 黏膜

Humans Palliative Care Prospective Studies Quality of Life Retrospective Studies *Urinary Bladder Neoplasms/radiotherapy Radiotherapy bladder cancer bleeding palliation

膀胱癌 分子亚型 治疗反应 化疗 免疫治疗

*Carcinoma Transitional Cell/surgery Cystectomy/adverse effects Humans Neoplasm Recurrence Local *Urinary Bladder Neoplasms/surgery

Administration Intravesical *Aneurysm Infected/therapy Aorta Humans *Mycobacterium bovis *Urinary Bladder Neoplasms/drug therapy

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Biomarkers Tumor/*analysis Carcinoma Transitional Cell/*chemistry/*drug therapy Humans Neoadjuvant Therapy Prognosis Urinary Bladder Neoplasms/*chemistry/*drug therapy Biomarkers Nac Neoadjuvant systemic therapy Ucb bladder cancer systematic review

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma